Kintor Pharmaceutical Ltd

HKSE:09939 (China)   Ordinary Shares
HK$ 1.12 (+0.9%) May 10
At Loss
P/B:
1.00
Market Cap:
HK$ 501.20M ($ 64.14M)
Enterprise V:
HK$ 283.14M ($ 36.24M)
Volume:
1.03M
Avg Vol (2M):
1.70M
Also Trade In:
Volume:
1.03M
At Loss
Avg Vol (2M):
1.70M

Business Description

Description
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.
Name Current Vs Industry Vs History
Cash-To-Debt 1.79
Equity-to-Asset 0.53
Debt-to-Equity 0.55
Debt-to-EBITDA -0.24
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 64.02
9-Day RSI 62.28
14-Day RSI 58.9
6-1 Month Momentum % -71.34
12-1 Month Momentum % -83.21

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.1
Quick Ratio 2.1
Cash Ratio 2.03
Days Inventory 5382.89
Days Payable 661.71

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -6.6
Shareholder Yield % -3.73

Profitability Rank

Name Current Vs Industry Vs History
ROE % -96.14
ROA % -65.73
ROIC % -126.87
ROC (Joel Greenblatt) % -200.46
ROCE % -79.08

Financials (Next Earnings Date:2024-08-28 Est.)

HKSE:09939's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Kintor Pharmaceutical Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil HK$)
EPS (TTM) (HK$) -2.702
Beta -0.13
Volatility % 54.36
14-Day RSI 58.9
14-Day ATR (HK$) 0.086553
20-Day SMA (HK$) 0.982
12-1 Month Momentum % -83.21
52-Week Range (HK$) 0.81 - 5.34
Shares Outstanding (Mil) 447.5

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Kintor Pharmaceutical Ltd Filings

Filing Date Document Date Form
No Filing Data

Kintor Pharmaceutical Ltd Stock Events

Financials Calendars
Event Date Price(HK$)
No Event Data

Kintor Pharmaceutical Ltd Frequently Asked Questions

What is Kintor Pharmaceutical Ltd(HKSE:09939)'s stock price today?
The current price of HKSE:09939 is HK$1.12. The 52 week high of HKSE:09939 is HK$5.34 and 52 week low is HK$0.81.
When is next earnings date of Kintor Pharmaceutical Ltd(HKSE:09939)?
The next earnings date of Kintor Pharmaceutical Ltd(HKSE:09939) is 2024-08-28 Est..
Does Kintor Pharmaceutical Ltd(HKSE:09939) pay dividends? If so, how much?
Kintor Pharmaceutical Ltd(HKSE:09939) does not pay dividend.

Press Release

Subject Date
No Press Release